News|Articles|November 19, 2026

Experts Explore Individualized Treatment Strategies for Psoriasis

Experts explore individualized plaque psoriasis treatment, highlighting biologic selection, adherence, comorbidities, and patient-centered care.

As treatment options for plaque psoriasis continue to expand, clinicians face increasingly complex decisions surrounding systemic therapy selection, treatment adherence, and long-term disease management. In a 13-part Dermatology Times Case-Based Peer Perspectives series, Navigating Plaque Psoriasis Treatment: A Patient-Centered Approach to Therapy Selection, Christopher Bunick, MD, PhD, associate professor of dermatology at Yale School of Medicine, moderated a discussion with April Armstrong, MD, MPH, professor and chief of dermatology at UCLA, examining practical strategies for individualizing care across 3 clinical cases.

The series addressed systemic treatment eligibility, biologic efficacy and safety, comorbidities, dosing convenience, and barriers to treatment access. A firsthand patient perspective further illustrated the importance of shared decision-making and developing sustainable treatment strategies.

Recognizing When to Escalate Beyond Topical Therapy

The series opened with a discussion of systemic treatment eligibility and the limitations of relying exclusively on body surface area (BSA) to assess psoriasis severity.

Armstrong highlighted International Psoriasis Council recommendations that consider disease involving high-impact areas, including the scalp, nails, palms, soles, and genital region, as well as inadequate response to topical treatment, when determining eligibility for systemic therapy.

The experts emphasized that treatment decisions should reflect the broader impact of psoriasis on daily functioning, quality of life, and the patient's ability to maintain an effective regimen.

In the first clinical case, a 39-year-old roofing contractor presented with an 8-year history of plaque psoriasis affecting approximately 15% of his BSA. His symptoms were exacerbated by sweating, sun exposure, and friction from occupational equipment, while obesity, hypertension, and a family history of premature coronary artery disease introduced additional treatment considerations.

Despite extensive disease involvement, the patient had relied primarily on topical corticosteroids, which he used inconsistently.

Armstrong explained that extensive topical treatment may become impractical for patients with physically demanding occupations, supporting consideration of systemic therapies that offer sustained disease control with a more manageable treatment burden.

The experts also discussed the importance of screening for comorbidities, including psoriatic arthritis and cardiometabolic conditions, before selecting systemic treatment.

Balancing Biologic Efficacy, Safety, and Long-Term Durability

Building on the first case, Bunick and Armstrong examined how clinicians can select among available biologic therapies for patients without previous systemic treatment experience.

Armstrong emphasized 3 important characteristics when evaluating treatment options: speed of onset, depth of response, and durability of efficacy.

Although these factors are sometimes viewed as competing priorities, she explained that contemporary biologic therapies may offer both substantial skin clearance and sustained long-term responses.

The discussion also addressed the importance of incorporating comorbidities into treatment decisions rather than focusing exclusively on skin-related outcomes.

For patients with obesity, diabetes, cardiovascular risk factors, or other inflammatory conditions, the experts emphasized the value of comprehensive disease assessment and individualized treatment planning.

Simplifying Treatment for Older Adults With Psoriasis

The second case involved a 72-year-old woman with late-onset plaque psoriasis affecting approximately 12% of her BSA. She reported itching that interfered with walking and sleep, while osteoarthritis of the hands complicated topical medication application.

Her medical history included type 2 diabetes, and previous treatments included topical corticosteroids, roflumilast, and oral apremilast. However, she frequently missed oral doses because of changes in her daily routine.

Armstrong emphasized that treatment selection for older adults should account for functional limitations, medication burden, and the practical challenges of maintaining prescribed regimens.

The experts challenged assumptions that advanced age alone should discourage biologic treatment, instead advocating for individualized safety assessments that consider comorbidities, concomitant medications, and overall health.

The discussion also explored the potential benefits of biologics with extended dosing intervals and health care professional–administered injections.

Bunick highlighted how office-based administration may help patients experiencing dexterity limitations or difficulties with self-injection, while Armstrong discussed the importance of insurance coverage and Medicare reimbursement when evaluating treatment accessibility.

The experts further examined real-world persistence data involving interleukin-23 inhibitors, emphasizing that treatment success depends not only on clinical efficacy but also on patients' ability to continue therapy over time.

Addressing Adherence and High-Impact Disease Sites

The third case featured a 34-year-old hospital administrator working night shifts who experienced difficulties maintaining her biologic treatment regimen.

The patient had psoriasis involving high-impact areas, including the scalp and nails, underscoring the importance of assessing disease burden beyond conventional BSA measurements.

Armstrong emphasized the need to distinguish inadequate treatment efficacy from poor adherence before changing therapies.

The experts discussed barriers associated with self-administered biologics, including scheduling difficulties, injection technique, medication storage, and treatment-related anxiety.

Rather than automatically switching therapies after an inadequate response, Armstrong recommended identifying whether additional education, administration support, or a different dosing schedule could improve treatment outcomes.

The patient ultimately selected tildrakizumab, an IL-23 inhibitor administered every 12 weeks in a health care setting, allowing treatment to better accommodate her demanding schedule.

The panel also reviewed site-specific efficacy data involving tildrakizumab, secukinumab, and ustekinumab, discussing how clinical evidence for scalp and nail psoriasis can inform treatment selection.

Long-term monitoring, breakthrough symptoms, and potential loss of response were additional considerations, with the experts emphasizing the importance of reassessing treatment effectiveness and adherence throughout the course of care.

Patient Perspective Reinforces the Importance of Access and Affordability

The series concluded with a patient perspective from Keki Mody, an 83-year-old patient of Bunick who described his experience managing psoriasis over approximately 3 decades.

Mody discussed his progression from topical therapies to biologic treatment, as well as how comorbid medical conditions, including monoclonal gammopathy of undetermined significance (MGUS), influenced his treatment journey.

Insurance coverage and out-of-pocket expenses emerged as significant barriers to accessing effective treatment.

Following discussions with Bunick, Mody transitioned to tildrakizumab through Medicare Part B coverage and reported meaningful improvement in disease control.

His experience highlighted how treatment affordability, dosing convenience, and access to health care professional–administered therapy can influence long-term treatment decisions.

The patient perspective reinforced a central theme throughout the series: Effective psoriasis management requires more than identifying a therapy capable of achieving skin clearance. Clinicians must also consider whether patients can access, afford, and maintain treatment over time.

Advancing Patient-Centered Psoriasis Management

Across the 13 episodes, Bunick and Armstrong emphasized that individualized plaque psoriasis management requires consideration of disease severity, comorbidities, treatment history, functional limitations, and patient preferences.

The discussions highlighted the importance of recognizing systemic treatment eligibility beyond BSA thresholds, evaluating biologic efficacy and safety, and addressing adherence barriers before assuming treatment failure.

Ultimately, the series underscored the value of shared decision-making and practical treatment strategies that support sustained disease control while accommodating patients' medical, financial, and lifestyle needs.

References

  1. 1. Bunick CG, Armstrong A. Navigating plaque psoriasis treatment: a patient-centered approach to therapy selection. Dermatology Times. 2026. Accessed November 10, 2026. https://www.dermatologytimes.com/case-based-peer-perspective/navigating-plaque-psoriasis-treatment-a-patient-centered-approach-to-therapy-selection
  2. Bunick CG, Armstrong A. Choosing first-line biologics for treatment-naive plaque psoriasis patients. Dermatology Times. October 5, 2026. https://www.dermatologytimes.com/view/choosing-first-line-biologics-for-treatment-naive-plaque-psoriasis-patients
  3. Bunick CG, Armstrong A. Access, adherence, and dosing frequency in older psoriasis patients. Dermatology Times. October 19, 2026. https://www.dermatologytimes.com/view/access-adherence-and-dosing-frequency-in-older-psoriasis-patients

Related to this article

TanPrevent and the Case for Preventing Thousands of Melanomas
Learn why indoor tanning remains a preventable source of melanoma, what research suggests about why some patients experience difficulty stopping, and how a clinical pilot called TanPrevent could connect education with follow-up support to help them quit and stay quit.